Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | SHBG | P04278 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 7/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245832 | 0.91 | MEN1 (0.70) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL8168221 | 0.91 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL29535974 | 0.91 | MEN1 (0.70) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL31511913 | 0.91 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL30511126 | 0.90 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL9730692 | 0.86 | MEN1 (0.67) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| Ononetin SCHEMBL2948430 | 0.82 | NPC1 (1.00) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| Ononetin SCHEMBL30203900 | 0.82 | NPC1 (1.00) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL1245285 | 0.82 | NPC1 (0.68) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL29535799 | 0.82 | NPC1 (0.68) | SMN1; SMN2HPGDMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861402-B1 | ISOFLAVONOID DIMERS | NOVOGEN RES PTY LTD (AU) | 2011-01-26 | — | — | EP | disclosed |
| EP-1861402-B1 | ISOFLAVONOID DIMERS | NOVOGEN RES PTY LTD (AU) | 2011-01-26 | — | — | EP | disclosed |
| WO-2011000566-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEGATIVE-SENSE SSRNA VIRUS INFECTIONS | SAVIRA PHARMACEUTICALS GMBH (AT) | 2011-01-06 | — | — | WO | disclosed |
| US-7700644-B2 | Such as 4,9-Dihydroxy-14,15-dimethoxy-12a-(3',4'-dimethoxyphenyl)-2, 11-dioxa-(1H,12H)-6b,6c,12a,16b-tetrahydronaphtho[1,2-g]chrysene via dimerisation of 3-phenylchroman | NOVOGEN RESEARCH PTY LTD (AU) | 2010-04-20 | — | — | US | disclosed |
| US-7700644-B2 | Such as 4,9-Dihydroxy-14,15-dimethoxy-12a-(3',4'-dimethoxyphenyl)-2, 11-dioxa-(1H,12H)-6b,6c,12a,16b-tetrahydronaphtho[1,2-g]chrysene via dimerisation of 3-phenylchroman | NOVOGEN RESEARCH PTY LTD (AU) | 2010-04-20 | — | — | US | disclosed |
| US-7700644-B2 | Such as 4,9-Dihydroxy-14,15-dimethoxy-12a-(3',4'-dimethoxyphenyl)-2, 11-dioxa-(1H,12H)-6b,6c,12a,16b-tetrahydronaphtho[1,2-g]chrysene via dimerisation of 3-phenylchroman | NOVOGEN RESEARCH PTY LTD (AU) | 2010-04-20 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| EP-1861402-A1 | ISOFLAVONOID DIMERS | Novogen Research Pty. Ltd. (AU) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006099681-A1 | ISOFLAVONOID DIMERS | NOVOGEN RESEARCH PTY LTD (AU) | 2006-09-28 | — | — | WO | disclosed |
| EP-0478558-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED ISOFLAVONE DERIVATIVES | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1994-02-02 | — | — | EP | disclosed |
| US-5247102-A | Cyclization of a resorcinol derivative with ethyl orthoformate in the presence of a base | CHINOIN GYOGYSZER- ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1993-09-21 | — | — | US | disclosed |
| WO-1991015483-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED ISOFLAVONE DERIVATIVES | CHINOIN GYÓGYSZER ÉS VEGYÉSZETI TERMÉKEK GYÁRA RT (HU) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306140-A1 | Isoflavonoid Dimers | CDK2, CDK20, F2 | SMN1; SMN2 3742/4885HPGD 54/4885MEN1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.